Title
Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers.

Permalink
https://escholarship.org/uc/item/4n095936

Journal
JCO precision oncology, 4(4)

ISSN
2473-4284

Authors
Vu, Peter
Khagi, Yulian
Riviere, Paul
et al.

Publication Date
2020

DOI
10.1200/po.19.00204

Peer reviewed
Total number of alterations in liquid biopsies is an independent predictor of survival in patients with advanced cancers

Peter Vu¹, Yulian Khagi¹, Paul Riviere¹, Aaron Goodman², Razelle Kurzrock¹

¹Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA
²Division of Blood and Marrow Transplantation, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA

Running Head: Total number of alterations in liquid biopsies is prognostic

Corresponding Author:
Peter Vu, MD
Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
3855 Health Sciences Drive, MC #0829
La Jolla, California 92093-0658
(858) 657-5281
(858) 657-5348 (Fax)
p0vu@ucsd.edu

Conflicts of Interest:
Dr. Razelle Kurzrock has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant Health, as well as consultant fees from Sequenom, Loxo and Actuate Therapeutics, speaker fees from Roche, and an ownership interest in IdbyDNA and Curematch, Inc
Dr. Goodman receives speaking fees from Seattle Genetics and consulting fees from Jazz Pharmaceuticals.
Dr. Khagi receives speaking fees from Sanofi Genzyme.

Financial Support:
Funding was provided in part by the Joan and Irwin Jacobs Fund and by National Cancer Institute grants P30 CA023100 (RK) and by the National Institutes of Health, Grant TL1TR001443 (PR).

Context Summary:
Key objective: Can we utilize liquid biopsies to obtain prognostic information for patients with advanced cancers?
Knowledge generated: We demonstrate that an increasing number of genomic alterations found on liquid biopsy correlates with progressively worse survival in patients with gastrointestinal and other advanced cancers, independent of the percent ctDNA or allele fraction.
Relevance: The total number of alterations found on a liquid biopsy may be a marker of more aggressive tumor biology and has the potential to become a clinically meaningful, tissue-
agnostic biomarker for use in advanced cancers and warrants further testing in a prospective manner.

Revised December 23, 2019

ABSTRACT

PURPOSE: Studies have demonstrated an association between quantity of circulating tumor DNA (ctDNA) and poorer survival. We investigated the relationship between %ctDNA, total number of ctDNA alterations, and overall survival (OS) in liquid biopsies.

PATIENTS AND METHODS: Overall, 418 patients with blood-based next generation sequencing (54 to 73 genes: Guardant Health) were analyzed. Eligible patients included those who had solid tumor malignancies and never received immunotherapy treatment, which may alter the survival curve in patients with high mutational burden.

RESULTS: Patients with a high (≥5%) %ctDNA had significantly shorter OS versus those with intermediate (≥0.4% to <5%) or low (<0.4%) values (median OS, 7.0 vs. 14.1 vs. not reached (NR) months, respectively; \( P < .0001 \)). Patients with a high (≥5) total number of alterations had significantly shorter OS versus those with intermediate (≥1.46 to <5), low (<1.46), or no alterations (median OS 4.6 vs. 11.7 vs. 21.3 vs. NR months, respectively; \( P < .0001 \)). The total number of alterations correlated with %ctDNA (\( r = 0.85; 95\% \text{ CI}, 0.81-0.87; P < 0.0001 \)). However, only an intermediate to high total number of alterations (≥1.46) was an independent predictor of worse OS (hazard ratio 1.96; 95% CI, 1.30-2.96; \( P = 0.0014 \); multivariate analysis).

CONCLUSION: We demonstrate that the total number of alterations and %ctDNA have prognostic value and correlate with one another, but only the total number of alterations was independently associated with survival outcomes. Our findings suggest that the total
number of alterations in plasma may be an indicator of more aggressive tumor biology and therefore poorer survival.
INTRODUCTION

Five-year survival rates are incredibly variable among cancer types, ranging from over 90% in prostate cancer to less than 8% in pancreas cancer, and depend heavily on clinical and pathologic stage. Although repeat tissue biopsies during the course of treatment or at the time of progression may provide clinically important information, such biopsies are not routinely performed because they can be technically difficult, time consuming, medically invasive, and lead to complications. On the other hand, liquid biopsies, or cell-free DNA (cfDNA) obtained from blood plasma that contains fragments of circulating tumor DNA (ctDNA) shed from tumor cells into the bloodstream, can identify new actionable alterations and be performed repeatedly with minimal procedural risk. ctDNA can then be analyzed using technologies such as digital polymerase chain reaction (PCR) to detect specific known somatic variants (e.g., EGFR T790M) or next-generation sequencing (NGS) that uses massive parallel sequencing to detect up to thousands of somatic and germline alterations in a single run. In addition, genomic alterations found on liquid biopsies are often concordant with alterations found on tissue biopsy when obtained within close proximity to one another.

A number of studies have demonstrated that there is an association between higher amounts of cfDNA or ctDNA and poorer survival, perhaps because percent ctDNA (\%ctDNA) correlates with tumor burden. For the most part, these reports dichotomized the level of cfDNA or ctDNA at a cut-point (often but not always at \(\sim 5\%\) or 10% ctDNA). In the case of surgical candidates, the cut-points may be lower. For instance, Baumgartner and colleagues found that pre-operative levels of \%ctDNA \(\geq 0.25\%\) in patients with peritoneal carcinomatosis were an independent predictor of shorter progression-free survival.
In the current study, we sought to more comprehensively examine the relationship between %ctDNA versus the total number of alterations found in liquid biopsies and outcome.
MATERIALS AND METHODS

Patient Data

Overall, 418 consecutive eligible patients at the University of California San Diego who had NGS (54 to 73 genes: Guardant Health) performed on ctDNA derived from liquid (blood) biopsies were analyzed. Eligible patients included those who had solid tumor malignancies, never received immunotherapy treatment, and were evaluable for clinical correlations including overall survival (OS) from ctDNA collection date. Patients had advanced/metastatic (stage IV) disease (except for patients with CNS tumors) at the time of ctDNA analysis. Immunotherapy-treated patients were omitted because a correlation with blood or tissue tumor mutational burden has been associated with better immunotherapy response and might therefore alter the survival curve. Patients with amplifications only in ctDNA were omitted because the %ctDNA for amplifications could not be determined. In addition to OS evaluation, patients’ data was also collected and analyzed for %ctDNA (the alteration with the highest allele fraction was calculated from all alterations, including variants of unknown significance (VUS)), total number of VUSs, and total number of alterations (which included VUSs). Percent ctDNA was evaluated as a continuous variable as well as using a cut-point of ≥5%, as this threshold had been found to be significant in prior studies. All studies and analyses were performed in accordance with the ethical guidelines of the Declaration of Helsinki and the Belmont Report per a University of California San Diego, Internal Review Board-approved protocol (NCT02478931) and the investigational treatment protocols for which the patients gave written consent. All human investigations were performed after approval by a local Human Investigations Committee and in accordance with an assurance filed with and approved by the Department of Health and Human Services.

tDNA Sequencing
Sequencing was performed by a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited clinical laboratory, Guardant Health, Inc. (http://www.guardanthealth.com). The Guardant360 (54 to 73 gene) panel identifies characterized and VUS tumor-related genomic alterations within cancer-related genes. All values for the total number of ctDNA alterations and the number of VUSs were corrected for the length (kilobase pairs, kbp) of DNA sequenced based on the date sequencing was performed and multiplied by 100 (Supplemental Table 1). All data was analyzed from the time of ctDNA collection from plasma (two 10-mL blood tubes). This ctDNA assay has a sensitivity and specificity of >85% and >99.9999%, respectively, for detection of single-nucleotide variants in tumor tissue of advanced cancer patients. 

Statistical analysis:
Statistical analysis was performed by PR. Hazard ratios (HR) for survival were calculated by comparing OS above and below cutoffs and performed from the time of ctDNA collection; dichotomization for each variable (i.e., total number of alterations, total number of VUSs, %ctDNA) was performed at the median. Survival analyses were calculated by Kaplan-Meier analysis using log-rank (Mantel-Cox) test to generate p-values, hazard ratios, and confidence intervals (CI). Linear regressions were performed using the least squares method. Multivariate analyses were conducted using the Wald chi-square test from a Cox proportional hazards model that included all variables with P≤0.05 in univariate analyses (i.e., gender, age, total number of alterations, %ctDNA), with the exception of VUSs because these alterations are already encompassed within the total number of alterations variable. Patients alive at the time of last follow up were censored at that date. Associations between %ctDNA and total number of alterations were determined using Spearman’s rank-order correlation. Bootstrapping utilizing
random sampling with replacement ($N = 1,000$ bootstrap samples) and multiple logistic regression analysis was performed, permitting the data of the sample study to be used as a surrogate for a larger population to validate the model. This method can be used when the sample size is too small to be split into training and validation sets and there is no independent cross-validation cohort, as is the case in our study. Statistical analyses were carried out using Graph-Pad Prism version 7.0 (San Diego, CA, USA) and R version 3.5 (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org/).
RESULTS

**Patient Characteristics:**

This study included 418 patients who had NGS performed on plasma-derived ctDNA and did not receive immunotherapy treatment. The median age at diagnosis was 60 years (range, 14-92) and the number of men (n=191/418; 46%) and women (n=227/418; 54%) were balanced. The most common tumor types included gastrointestinal (GI) (n=173/418; 41.4%), thoracic (n=94/418; 22.5%), central nervous system (n=51/418; 12.2%), and others (n=100/418; 23.9%) (Table 1). After correcting for the kbp length of DNA sequenced for each sample, the median total number of ctDNA alterations (including VUSs) per patient was 1.46 (range, 0-78.8); the median total number of VUS alterations per patient was 0.66 (range, 0-64.2); and the median %ctDNA was 0.4% (range, 0-80.3%) (Table 1). Among patients with GI tumors, the median total number of ctDNA alterations was 1.46 (range, 0-78.8) and the median %ctDNA was 0.5% (range, 0-75%).

**Factors Correlating with Survival in Univariate Analysis**

The following factors showed significant correlations with poorer survival in univariate analysis: gender, older age (dichotomized at the median of 60 years), higher total number of alterations/kbp DNA (dichotomized at the median of 1.46), greater number of VUS alterations/kbp DNA (dichotomized at the median of 0.66), and higher %ctDNA (dichotomized at the median of 0.4%) (Table 1). Tumor organ of origin was not found to be significantly correlated with differences in survival.

Patients with %ctDNA greater than or equal to the median of 0.4% had inferior OS compared to those with less than 0.4% (HR, 2.04; 95% CI, 1.48-2.83; \( P<0.0001 \)) (Table 1). Furthermore, patients with a high %ctDNA (≥5%) had a significantly shorter OS.
compared to those who had an intermediate (≥0.4% to <5%) or low (<0.4%) value (median OS 7.0 vs. 14.1 vs. not reached months, respectively; \( P<.0001 \)) (Figure 1).

Among patients with GI tumors, those with %ctDNA greater than or equal to the GI median of 0.5% had worse survival outcomes (HR, 2.46; 95% CI, 1.50-4.03; \( P<.0001 \); Table 2).

Likewise, patients with ≥1.46 total alterations/kbp DNA had statistically inferior OS compared to those who had less than the median of 1.46 total alterations/kbp DNA (HR, 2.42; 95% CI, 1.75-3.36; \( P<0.0001 \)) (Table 1). Patients with a high (≥5) total number of alterations/kbp DNA had significantly shorter OS compared to those who had an intermediate (≥1.46 to <5), low (<1.46), or no alterations (median OS 4.6 vs. 11.7 vs. 21.3 vs. not reached months, respectively; \( P<.0001 \)) (Figure 2). In the subset of patients with GI tumors, patients with greater than or equal to the median of 1.46 total alterations/kbp had worse survival outcomes (HR, 3.46; 95% CI, 2.09-5.72; \( P<0.0001 \); Table 2). Also, a higher number of VUS alterations/kbp DNA (≥0.66) was associated with worse OS compared to those with a lower number (<0.66) of VUS alterations/kbp (HR, 1.69; 95% CI, 1.24-2.30) (Table 1, Supplemental Figure 1).

Correlation between %ctDNA and total number of alterations

The following ctDNA variables showed significant correlations with one another: the %ctDNA and the total number of alterations tend to increase together (\( r=0.85; 95\% \text{ CI, 0.81-0.87; } P<0.0001 \)) (Figure 3) and the number of VUS alterations and total number of alterations tend to increase together (\( r=0.73; 95\% \text{ CI, 0.68-0.77; } P<0.0001 \)) (Supplemental Figure 2). To evaluate the influence of patients who had no detectable alterations (\( n=112 \)), we performed a sensitivity analysis removing these patients from the correlation calculations and found that there was still a significant (albeit attenuated)
correlation between %ctDNA and total number of alterations ($r = 0.61$, $p<0.0001$) as well as VUS and total number of alterations ($r = 0.60$, $p<0.0001$).

**Factors Correlating with Survival in Multivariate Analysis**

After accounting for gender, age, total number of alterations, and %ctDNA, a multivariable Cox proportional hazard regression model showed that age, sex, and the total number of alterations were independently prognostic for survival (Table 1). Specifically, patients with a high number of alterations ($\geq 1.46$) compared to those with fewer alterations ($<1.46$) had worse OS (HR 1.96; 95% CI, 1.30-2.96; $P=0.0014$). Although statistically significant in univariate analysis, higher %ctDNA ($\geq 0.4\%$) was not predictive of poorer survival compared to those with lower %ctDNA ($<0.4\%$) (HR, 1.31; 95% CI, 0.87-1.97; $P=0.19$) in multivariate analysis (Table 1). We also analyzed the subset of patients with GI tumors and found similar results. Although univariate analyses of the GI subset of patients showed that both a high number of alterations ($\geq 1.46$) and higher %ctDNA ($\geq 0.5\%$) had prognostic value, only the total number of alterations (HR, 3.23; 95% CI, 1.73-6.03; $P<0.0001$), not the %ctDNA (HR, 1.36; 95% CI, 0.73-2.51; $P=0.34$), was associated with worse outcomes in the multivariate model (Table 2).

**Analysis with bootstrapping method**

Bootstrapping with multiple logistic regression was performed on all variables with $P \leq 0.05$ in univariate analysis, which included sex, age, total number of alterations, and %ctDNA. Among these characteristics, only total number of alterations was significantly associated with survival ($P<0.0001$; Table 1).

**DISCUSSION**
Liquid biopsies have been incorporated into clinical practice as a means to obtain noninvasive molecular profiling in order to identify specific oncogenic driver mutations or other alterations that can guide treatment selection. In this study, we evaluated the relationship between the total number of alterations and the %ctDNA detected by liquid biopsy and survival outcomes in 418 patients with advanced cancers. The objective was to explore the potential prognostic value of blood-based NGS. It should be noted that we adjusted for changes in sequencing length by correcting the total number of alterations and VUSs for the amount of DNA sequenced. In addition, we intentionally excluded patients who subsequently received immunotherapy treatment, as several studies have suggested that the use of immune checkpoint inhibitors may alter the survival curve in patients with increased tumor mutational burden\textsuperscript{19, 20, 23}.

We demonstrate that both the total number of alterations and the %ctDNA have prognostic value and correlate with one another, but only an intermediate to high (≥1.46) total number of alterations/kbp (and not high %ctDNA) was independently associated with worse survival outcomes in multivariate analysis in patients with GI tumors (Table 2) as well as in patients with a diverse group of advanced cancers (Table 1). These findings were then internally validated using bootstrap resampling. Our findings suggest that more alterations per kbp DNA detected in plasma may be a better indicator of more aggressive tumor biology and therefore poorer survival than %ctDNA. It is also plausible that the higher number of alterations and accompanying aggressive biology results in a higher tumor burden that yields a higher %ctDNA (rather than vice versa).

A strength of our study is that we utilized sequencing technology that allows for the detection of %ctDNA at a low level with high sensitivity and very high specificity\textsuperscript{21, 24}. In comparison, some prior studies have utilized low-depth sequencing, which is less
capable at detecting ctDNA. As a result, these studies were only able to conclude that the presence of ctDNA was associated with worse outcomes compared to the absence of detectable ctDNA. Indeed, Yang et al proposed that the presence or absence of ctDNA should be added to the TNM staging classification of tumors because it has diagnostic, therapeutic, and prognostic value. When greater depth of ctDNA sequencing was used, prior studies have reported that %ctDNA is correlated with worse survival and also with increased tumor volume. We also demonstrated that %ctDNA correlates with survival measured from the time of blood draw (Figure 1), which suggests that the association between %ctDNA and outcomes may be more reflective of tumor burden.

There are several limitations to our findings given the retrospective nature of the analysis. Although our study utilized a relatively large sample of 418 patients, we included a diverse group of advanced cancers and, therefore, our findings may not be applicable to certain tumor types. On the other hand, the variety of tumor types in our study may make our findings more generalizable across advanced cancers. However, we also performed the analyses a cohort of 173 patients with gastrointestinal tumors and found similar results (Table 2). In addition, 112 patients in this study had no detectable %ctDNA, which may be due to low disease burden or due to limitations of the ctDNA sequencing technique. It should also be noted that there were different number of subgroups in the analysis of %ctDNA and number of ctDNA alterations; hence the conclusion that the total number of alterations and %ctDNA have prognostic value and correlate with one another, but only the total number of alterations was independently associated with survival outcomes will need to be further examined and validated. Also, we do not know if this patient population is comparable to those who were not analyzed for ctDNA because physicians chose not to perform the analysis, or to patients who were
lost to follow up early and hence were invaluable. Finally, patients had a diverse array of prior treatments, some of which could have confounded the results; patients treated with immunotherapy were excluded because cancers with higher mutational burden/number appear to do better on this modality.

In conclusion, to our knowledge, this is the first demonstration that the total number of alterations and %ctDNA are highly correlated and have prognostic value. Nevertheless, in multivariate analysis, only the total number of alterations was independently predictive of overall survival. Understanding the prognostic value of ctDNA is important in and of itself, but also has implications as a confounder, since ctDNA is being utilized as a predictive marker for the efficacy of drugs such as immunotherapy\textsuperscript{20}. To summarize, the total number of alterations has the potential to become a clinically meaningful, tissue-agnostic biomarker for use in advanced cancers and warrants further testing in a prospective manner.

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68:7–30, 2018

2. Jahr S, Hentze H, Englisch S, et al: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665, 2001

3. Ikeda S, Schwaederle M, Mohindra M, et al: MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. J Hematol Oncol 11:76, 2018

4. Merker JD, Oxnard GR, Compton C, et al: Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol JCO2017768671, 2018
5. Corcoran RB, Chabner BA: Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med 379:1754-1765, 2018

6. Alekseyev YO, Fazeli R, Yang S, et al: A Next-Generation Sequencing Primer-How Does It Work and What Can It Do? Acad Pathol 5:2374289518766521, 2018

7. Schwaederlé MC, Patel SP, Husain H, et al: Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res 23:5101-5111, 2017

8. Riviere P, Fanta PT, Ikeda S, et al: The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. Mol Cancer Ther 17:297-305, 2018

9. Adalsteinsson VA, Ha G, Freeman SS, et al: Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun 8:1324, 2017

10. Schwaederle M, Husain H, Fanta PT, et al: Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res 22:5497-5505, 2016

11. Abbosh C, Birkbak NJ, Wilson GA, et al: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545:446-451, 2017

12. van der Drift MA, Hol BEA, Klaassen CHW, et al: Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68:283-287, 2010

13. Ai B, Liu H, Huang Y, et al: Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget 7:44583-44595, 2016

14. Ocaña A, Díez-González L, García-Olmo DC, et al: Circulating DNA and Survival in Solid Tumors. Cancer Epidemiol Biomarkers Prev 25:399-406, 2016
15. Baumgartner JM, Raymond VM, Lanman RB, et al: Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. Ann Surg Oncol 25:2400-2408, 2018

16. Mehrotra M, Singh RR, Loghavi S, et al: Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget 9:10259-10271, 2018

17. Rossi G, Mu Z, Rademaker AW, et al: Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. Clin Cancer Res 24:560–568, 2018

18. Stover DG, Parsons HA, Ha G, et al: Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol 36:543–553, 2018

19. Goodman AM, Kato S, Bazhenova L, et al: Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther 16:2598–2608, 2017

20. Khagi Y, Goodman AM, Daniels GA, et al: Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res 23:5729–5736, 2017

21. Lanman RB, Mortimer SA, Zill OA, et al: Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One 10:e0140712, 2015

22. Steyerberg EW, Harrell FE Jr, Borsboom Gj, et al: Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54:774–781, 2001
23. Goldberg SB, Narayan A, Kole AJ, et al: Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin Cancer Res 24:1872–1880, 2018

24. Wan JCM, Massie C, Garcia-Corbacho J, et al: Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17:223–238, 2017

25. Dawson S-J, Tsui DWY, Murtaza M, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199–1209, 2013

26. Lecomte T, Berger A, Zinzindohoué F, et al: Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100:542–548, 2002

27. Yang M, Forbes ME, Bitting RL, et al: Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311–323, 2018
Table 1: Univariate and multivariate analyses of patient and ctDNA characteristics on survival (n = 418)\(^a\)

| Variable | Group | N=418 (%) | Median OS (months) | HR (95% CI) Univariate\(^e\) | P value Univariate | HR (95% CI) Multivariate\(^f\) | P value Multivariate | P value Bootstrap \(^h\) |
|----------|-------|-----------|--------------------|--------------------------------|-------------------|------------------------|---------------------|------------------------|
| Sex      | Women | 227 (54%) | 79                 | Reference Group               | 0.01              | Reference Group        | 0.04                | 0.1                    |
|          | Men   | 191 (46%) | 53                 | 1.47 (1.08 – 2.00)            |                   | 1.39 (1.02 - 1.89)     |                     |                        |
| Age      | ≤60 years | 225 (54%) | 76.6               | Reference Group               | 6.1x10^-4         | Reference Group        | 0.01                | 0.26                   |
|          | >60 years | 193 (46%) | 50.4               | 1.72 (1.26 – 2.34)            |                   | 1.50 (1.09 - 2.05)     |                     |                        |
| Tumor Type | Gastrointestinal | 173 (41%) | 54.6               | 1.59 (1.08 – 2.34)            | 0.12              |                        |                     |                        |
|          | Thoracic | 94 (22%) | 72.7               | 1.28 (0.80 – 2.03)            |                   |                        |                     |                        |
|          | CNS | 51 (12%) | 61.4               | 1.15 (0.69 – 1.94)            |                   |                        |                     |                        |
|          | Other\(^d\) | 100 (24%) | 87.1               | Reference Group               |                   |                        |                     |                        |
| (Total Alterations x 100 / kbp)\(^b\) | <1.46 | 203 (49%) | 104.8              | Reference Group               | 1.1x10^-7         | Reference Group        | 1.4x10^-3           | 1.8x10^-5 |
|          | ≥1.46 | 215 (51%) | 42.2               | 2.42 (1.75 – 3.36)            |                   | 1.96 (1.30 - 2.96)     |                     |                        |
| (VUS x 100 / kbp)⁸ | <0.66 | 207 (50%) | 87 | Reference Group | 8.9x10⁻⁴ | Omitted⁹ |
|-------------------|--------|-----------|----|-----------------|----------|---------|
| ≥0.66             | 211 (50%) | 53 | 1.69 (1.24 - 2.30) | | |

| %ctDNA² | <0.4 | 195 (47%) | 105 | Reference Group | 1.6x10⁻⁵ | |
|---------|------|-----------|----|-----------------|----------|---------|
| ≥0.4   | 223 (53%) | 50 | 2.04 (1.48 - 2.83) | | 1.31 (0.87 - 1.97) | 0.19 | 0.11 |

**Note:** All survival analyses were performed from the time of ctDNA collection

**Abbreviations:** CI = confidence interval; CNS = central nervous system; ctDNA = circulating tumor DNA; %ctDNA = percent circulating tumor DNA; HR = hazard ratio; kbp = kilobase pairs; NR = not reached; OS = overall survival; VUS = variants of unknown significance

⁸ Patients treated with immunotherapy were excluded
⁹ Dichotomization done at medians
¹⁰ Dichotomization done at medians of highest %ctDNA for each patient; alteration with highest %ctDNA was calculated from all alterations including VUSs. Patients with only amplifications were considered inevaluable and excluded. Kbp indicates the length of ctDNA sequenced: (See Methods)
¹² Other Tumor Type includes Breast (n=29), Head and Neck (n=21), Genitourinary (n=13), Gynecologic (n=18), Neuroendocrine, Sarcoma, Melanoma, and Unknown Primary
¹⁶ Hazard Ratio performed using log-rank
¹⁷ Variables with \( P \leq 0.05 \) in univariate analysis were included in the multivariate analysis. Separate analyses were done to include %ctDNA, total alterations
¹⁹ VUS was excluded from the multivariate analysis because it is encompassed within total alterations
² Boostrapping with multiple logistic regression analysis was conducted on characteristics with \( P \leq 0.05 \) in univariate analysis. P-value based on 1,000 bootstrap samples.
## Table 2: Univariate and multivariate analyses of patient and ctDNA characteristics and survival for gastrointestinal tumors (N = 173)

| Variable          | Group     | N=173 (%) | Median OS (months) | HR (95% CI) Univariate<sup>d</sup> | P value Univariate | HR (95% CI) Multivariate<sup>e</sup> | P value Multivariate<sup>e</sup> |
|-------------------|-----------|-----------|--------------------|------------------------------------|-------------------|---------------------------------------|----------------------------------|
| **Sex**           | Women     | 78 (45%)  | 19.7               | Reference Group                    | **0.025**         | **1.87 (1.13-3.06)**                  | **0.01**                         |
|                   | Men       | 95 (55%)  | 10.0               | 1.76 (1.08-2.88)                   |                   |                                       |                                  |
| **Age**           | ≤60 years | 93 (54%)  | 21.3               | Reference Group                    | **0.015**         | **1.78 (1.09-2.90)**                  | **0.02**                         |
|                   | >60 years | 80 (46%)  | 10.3               | 1.83 (1.13-2.97)                   |                   |                                       |                                  |
| **(Total Alterations x 100 / kbp)**<sup>b</sup> | <1.46     | 75 (43%)  | 38.9               | Reference Group                    | **1.3x10<sup>-6</sup>** | **3.23 (1.73-6.03)**                 | **2.4x10<sup>-4</sup>**           |
|                   | ≥1.46     | 98 (57%)  | 6.4                | 3.46 (2.09-5.72)                   |                   |                                       |                                  |
| **(VUS x 100 / kbp)**<sup>b</sup> | <0.73     | 84 (49%)  | 21.3               | Reference Group                    | **2.3x10<sup>-6</sup>** | **3.1 (1.95-5.02)**                  |                                 |
|                   | ≥0.73     | 89 (51%)  | 5.0                | 3.1 (1.95-5.02)                    |                   |                                       |                                  |
| **%ctDNA<sup>c</sup>** | <0.5      | 86 (50%)  | 21.3               | Reference Group                    | **3.8x10<sup>-4</sup>** | **1.36 (0.73-2.51)**                 | **0.34**                         |
|                   | ≥0.5      | 87 (50%)  | 9.3                | 2.46 (1.50-4.03)                   |                   |                                       |                                  |

**Note:** All survival analyses were performed from the time of ctDNA collection.
Abbreviations: CI = confidence interval; CNS = central nervous system; ctDNA = circulating tumor DNA; %ctDNA = percent circulating tumor DNA; HR = hazard ratio; kbp = kilobase pairs; NR = not reached; OS = overall survival; VUS = variants of unknown significance

a Patients treated with immunotherapy were excluded
b Dichotomization done at medians
c Dichotomization done at medians of highest %ctDNA for each patient; alteration with highest %ctDNA was calculated from all alterations including VUSs. Patients with only amplifications were considered inevaluable and excluded. Kbp indicates the length of ctDNA sequenced: (See Methods)
d Hazard Ratio performed using log-rank
e Variables with P ≤ 0.05 in univariate analysis were included in the multivariate analysis. Separate analyses were done to include %ctDNA, total alterations
f VUS was excluded from the multivariate analysis because it is encompassed within total alterations
Figure 1: Overall survival from ctDNA collection according to %ctDNA (n=418). Low to intermediate %ctDNA was dichotomized at the median of 0.4%. Intermediate to high %ctDNA was dichotomized at 5% because it had been found to be significant in prior studies [10]. The %ctDNA for each patient was calculated using the alteration with the highest allele fraction, including VUSs.
Figure 2: Overall survival from ctDNA collection according to total alterations, including VUS (n=418). Low to intermediate number of alterations was dichotomized at the median of 1.46 alterations.

Overall survival according to total alterations x 100 / kbp (n=418)

| Total Number of Alterations | No. of Patients | Median Overall Survival |
|-----------------------------|-----------------|------------------------|
| 0                           | 112             | Not Reached            |
| >0 to <1.46                 | 91              | 21.3 months            |
| ≥1.46 to <5                 | 162             | 11.97 months           |
| ≥5                          | 53              | 5.0 months             |

p <0.0001
Figure 3: Spearman correlation between %ctDNA and total number of alterations (n=418).

Correlation between %ctDNA and total alterations x 100 / kbp (n=418)

Spearman r = 0.85 (95% CI, 0.81 to 0.87)

p < 0.0001
**Supplemental Table 1:** Guardant360 ctDNA NGS panel and length of DNA sequenced.

| Number of Patients Analyzed | Number of Genes | Panel Start Date          | Size   |
|----------------------------|-----------------|---------------------------|--------|
| 47                         | 54              | 2014                      | 78 kbp |
| 140                        | 68              | February 2015             | 137 kbp|
| 174                        | 70              | October 2015              | 137 kbp|
| 56                         | 73              | November 2016             | 151 kbp|
| 1                          | 73              | September 2017            | 167 kbp*|

*Version 2 of the 73 gene panel with no changes to reportable results*
Supplemental Figure 1: Spearman correlation between VUS and total alterations (n=418).

Correlation between VUS x 100 / kbp and total alterations x 100 / kbp (n=418)

Spearman $r = 0.73$ (95% CI, 0.68 to 0.77)
$p = <0.0001$
Supplemental Figure 2: Overall survival from the date of ctDNA collection according to VUS (n=418). Dichotomization for low to intermediate number of alterations was done at the median of 0.7.

Overall survival according to VUS x 100 / kbp (n=418)

| VUS            | No. of Patients | Median Overall Survival |
|----------------|-----------------|-------------------------|
| <0.7           | 221             | 27.3 months             |
| >=0.7 to <2    | 139             | 12.8                    |
| >=2            | 58              | 5.0 months              |

p <0.0001
Supplemental Figure 3: Overall survival from ctDNA collection according to total alterations, including VUS (n=173), for the gastrointestinal patients only. Low to intermediate number of alterations was dichotomized at the median of 1.46.

- >1.46 to <5 alterations: 53 patients, 9.0 months
- >=5 alterations: 25 patients, 4.6 months

p <0.0001
**Supplemental Figure 4:** Overall survival from ctDNA collection according to %ctDNA (n=173). Low to intermediate %ctDNA was dichotomized at the median of 0.5%. Intermediate to high %ctDNA was dichotomized at 5% because it had been found to be significant in prior studies [10]. The %ctDNA for each patient was calculated using the alteration with the highest allele fraction, including VUSs.

**Overall survival in GI patients according to %ctDNA (n=173)**

| %ctDNA     | No. of Patients | Overall Survival |
|------------|-----------------|-----------------|
| <0.5       | 86              | 21.3 months     |
| ≥0.5 to <5 | 44              | 12.8 months     |
| ≥5         | 43              | 6.4 months      |

p = 0.0001